Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in gilead

Sales Of First Big COVID-19 Drug, Remdesivir, May Disappoint

Remdesivir has become the standard of care for patients hospitalized with severe COVID-19. But many doctors remain wary of using it more widely, raising questions about lofty analyst sales forecasts for a drug that could eventually be eclipsed by newer treatments.

Read More

Gilead To Pay $97 Million To Settle U.S. Kickback Probe

Gilead's actions enabled the Foster City, California-based drugmaker to boost revenue, ran from June 2007 to December 2010, and violated the federal False Claims Act, the department said.

Read More

Gilead To Buy Cancer Drugmaker Immunomedics For $21 Billion

Gilead's offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.

Read More

Gilead To Buy Cancer Drugmaker Immunomedics For $21 Billion

The offer will be funded with $15 billion in cash on hand, and through $6 billion in newly issued debt, according to the drugmaker.

Read More

Gilead Raises Sales Outlook To Include COVID-19 Treatment Remdesivir

Gilead's second-quarter sales fell nearly 10% from a year earlier to $5.1 billion, short of the average analyst estimate of $5.3 billion, according to Refinitiv.

Read More

Gilead Targets Remdesivir Supply For Two Million COVID-19 Patients By Year-End

Gilead's expectations of two million treatment courses suggests sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course

Read More

Six Indian companies applied to CDSCO for permission to manufacture, market Remdesivir drug: Health Ministry

Six Indian companies applied to CDSCO for permission to manufacture, market Remdesivir drug: Health Ministry

Read More

AstraZeneca Contacted Gilead Over Potential Megamerger

Gilead, AstraZeneca and other drugmakers, including Eli Lilly and Co, Pfizer and Merck & Co, are racing to develop vaccines or treatments for COVID-19

Read More

Gilead Trades That Made Millions On COVID-19 Drug News Raise Eyebrows

Gilead's shares jumped nearly 10% following a media report detailing encouraging partial data from trials of the U.S. company's experimental drug remdesivir in severe COVID-19 patients.

Read More

Gilead In Talks With Indian Drugmakers To Produce Remdesivir For Treatment Of COVID-19

The company is in active discussions with the Medicines Patent Pool, which Gilead has partnered with for many years, to licence remdesivir for developing countries.

Read More

Gilead Deepens Galapagos Ties With $5.1 Billion Deal

The investment in Galapagos, which comes nearly four years after the firms partnered to develop a drug targeting inflammatory diseases, includes an upfront payment of $3.95 billion and a $1.1 billion equity investment from Gilead.

Read More